Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oragenics Inc (OGEN)

Oragenics Inc (OGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,772
  • Shares Outstanding, K 4,265
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,570 K
  • EBIT $ -10 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.41

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6203 +65.24%
on 02/17/26
1.1100 -7.66%
on 03/11/26
+0.3800 (+58.91%)
since 02/12/26
3-Month
0.6111 +67.73%
on 02/12/26
1.1100 -7.66%
on 03/11/26
+0.1110 (+12.14%)
since 12/12/25
52-Week
0.6111 +67.73%
on 02/12/26
9.6000 -89.32%
on 06/02/25
-7.5250 (-88.01%)
since 03/12/25

Most Recent Stories

More News
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted...

OGEN : 0.9421 (+6.52%)
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION

SARASOTA, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal...

OGEN : 0.9421 (+6.52%)
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sites Potential first and only pharmacological treatment for the most prominent neurological...

OGEN : 0.9421 (+6.52%)
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy

Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI)  Fully prepared to initiate near-term clinical site onboarding and first patient dosing in...

OGEN : 0.9421 (+6.52%)
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program

Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapy Traumatic brain injuries affect more Americans each year...

OGEN : 0.9421 (+6.52%)
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care

Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment Sarasota, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN)...

OGEN : 0.9421 (+6.52%)
Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico

Sarasota, Fla., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”) today announced that it will be presenting at the upcoming Sequire Investor Summit 2026....

OGEN : 0.9421 (+6.52%)
Oragenics Q3 2025 Shareholder Update

Building on Solid Ground: From Vision to Execution Restoring Compliance, Advancing Innovation, Preparing for Clinical Milestones

OGEN : 0.9421 (+6.52%)
Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, announced today that it has regained...

OGEN : 0.9421 (+6.52%)
Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

Clinical-Stage Biotechnology Company Leverages Artificial Intelligence

OGEN : 0.9421 (+6.52%)

Business Summary

Oragenics Inc is a biotechnology company focused on the development and licensure of innovative products and technologies for improving human health.

See More

Key Turning Points

3rd Resistance Point 1.3063
2nd Resistance Point 1.2081
1st Resistance Point 1.0463
Last Price 0.9421
1st Support Level 0.7863
2nd Support Level 0.6881
3rd Support Level 0.5263

See More

52-Week High 9.6000
Fibonacci 61.8% 6.1662
Fibonacci 50% 5.1055
Fibonacci 38.2% 4.0449
Last Price 0.9421
52-Week Low 0.6111

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar